Securities code: 002252 securities abbreviation: Shanghai Raas Blood Products Co.Ltd(002252) Announcement No.: 2022-004 Shanghai Raas Blood Products Co.Ltd(002252)
Announcement on the resolutions of the 11th (Interim) meeting of the 5th board of directors
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
The 11th (Interim) meeting of the 5th board of directors of Shanghai Raas Blood Products Co.Ltd(002252) (“the company”) was notified by telephone and email on January 22, 2022 and held by communication at 3 p.m. on January 27, 2022.
There are 9 directors who should participate in the voting at this meeting and 9 directors who actually participate in the voting. The meeting was convened and presided over by Mr. Chen Jie, chairman and general manager of the company. The convening, convening and voting procedures of the meeting comply with the company law, the articles of association and other relevant provisions. On the premise of ensuring that all directors fully express their opinions, all directors present at the meeting unanimously adopted the following resolutions through voting:
1、 The proposal on nominating candidates for independent directors was deliberated and adopted
It is agreed to nominate Mr. Bingyu Wang as the candidate for independent director of the company (the candidate’s resume is attached), and elect him as the convener of the remuneration and assessment committee of the current board of directors and the member of the audit committee after his appointment as an independent director is reviewed and approved by the general meeting of shareholders.
Voting results: 9 in favor, 0 against and 0 abstention. This proposal still needs to be submitted to the first extraordinary general meeting of shareholders of the company in 2022 for deliberation. The qualification and independence of independent director candidates shall be filed and reviewed by Shenzhen Stock Exchange before they can be submitted to the general meeting of shareholders for voting.
The current independent directors of the company, Mr. Tan Jinsong, Mr. Yang Cuihua and Ms. Peng Ling, express the following independent opinions on the nomination of Mr. Bingyu Wang as the candidate for independent director of the board of directors:
1. The nomination procedure of independent director candidates this time complies with the relevant provisions of the company law and the articles of association, and the nomination is legal and effective;
2. After examination, the candidates for independent directors have the qualifications specified in the company law, the articles of association and other relevant laws and regulations, and there is no situation that they are not allowed to serve as directors or independent directors of the company as specified in the company law, the rules for independent directors of listed companies and the articles of Association; Not being placed on file for investigation by judicial organs for suspected crimes or being placed on file for investigation by CSRC for suspected violations of laws and regulations; It has not been punished by the CSRC and other relevant departments or the stock exchange. Candidates for independent directors have the knowledge and experience required to perform their duties and are competent for the duties of independent directors;
3. Agree to the nomination of independent director candidates and submit relevant proposals to the general meeting of shareholders for deliberation. The qualification and independence of independent director candidates can be submitted to the general meeting of shareholders of the company for voting after being reviewed by Shenzhen Stock Exchange.
2、 The proposal on convening the first extraordinary general meeting of shareholders in 2022 was deliberated and adopted
The company is scheduled to hold the first extraordinary general meeting of shareholders in 2022 by combining on-site and online voting on Monday, February 14, 2022. The equity registration date is Wednesday, February 9, 2022. The on-site meeting will be held at Nanjiao Hotel, No. 398, Zhanyuan Road, Nanqiao new town, Fengxian District, Shanghai.
Voting results: 9 in favor, 0 against and 0 abstention.
The notice on convening the first extraordinary general meeting in 2022 was published in securities times, China Securities News, Shanghai Securities News, securities daily and cninfo (www.cn. Info. Com. CN), For investors to consult.
It is hereby announced.
Shanghai Raas Blood Products Co.Ltd(002252) board of directors
January 28, 2002
Attachment: resume of independent director candidates
Mr. Bingyu Wang: New Zealand nationality, born in February 1966, with a postgraduate degree. He once served as sales manager of Shanghai Squibb Pharmaceutical Co., Ltd., senior product manager of Pfizer Pharmaceutical (Dalian), marketing director of Beijing Huajin Pharmaceutical Co., Ltd., general manager of Beijing meihuamei pharmaceutical consulting Co., Ltd., managing director of Guangzhou Baite Qiaoguang Medical Products Co., Ltd. He is currently the managing director of Beijing Hongbo gene Medical Technology Co., Ltd.
Mr. Bingyu Wang has no relationship with the company, directors, supervisors, senior managers and shareholders holding more than 5% of the shares of the company;
Mr. Bingyu Wang does not hold shares of the company, and there are no circumstances stipulated in the company law, the guidelines for self discipline supervision of listed companies of Shenzhen Stock Exchange No. 1 – standardized operation of listed companies on the main board, and the articles of association that he is not allowed to serve as an independent director of the company. He has not been filed for investigation by the judicial organ for suspected crimes or by the CSRC for suspected violations of laws and regulations, It has not been punished by the CSRC and other relevant departments or the stock exchange. Mr. Bingyu Wang is not a dishonest person.
